Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1264-1270

  Gavhed, Désirée ^a   Åkefeldt, Selma Olsson ^a   Österlundh, Gustaf ^b   Laurencikas, Evaldas ^a   Hjorth, Lars ^c   Blennow, Kaj ^b   Rosengren, Lars ^b   Henter, Jan Inge ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarkers; Central nervous system; Cerebrospinal fluid; Glial fibrillary acidic protein; Histiocytosis; Langerhans cell; Neurofilament protein; Tau proteins

Indexed keywords

CLADRIBINE; CORTICOSTEROID DERIVATIVE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN; MERCAPTOPURINE; METHOTREXATE; NEUROFILAMENT PROTEIN; TAU PROTEIN; VINBLASTINE; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN L;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BACKACHE; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTIOCYTOSIS X; HUMAN; INFANT; LIQUORRHEA; LUMBAR PUNCTURE; MALE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTDURAL PUNCTURE HEADACHE; PRESCHOOL CHILD; PRIORITY JOURNAL; ADOLESCENT; ADULT; BRAIN; COGNITIVE DEFECT; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; HYPOPHYSIS DISEASE; PATHOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; PUNCTURE; RADIOGRAPHY;

ADOLESCENT; BIOLOGICAL MARKERS; BRAIN; CEREBROSPINAL FLUID PROTEINS; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; MALE; NERVE DEGENERATION; NEUROFILAMENT PROTEINS; PITUITARY DISEASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SPINAL PUNCTURE; TAU PROTEINS; YOUNG ADULT;

EID: 70449729870     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22238     Document Type: Article

References (40)

1. Coury F, Annels N, Rivollier A, et al. Langerhans cell histiocytosis reveals a novel IL-17A-dependent pathway of dendritic cell fusion. Nature Med 2008;14:81-87.
2. Arico M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:247-258.
3. Henter JI, Tondini C, Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol 2004;50:157-174.
4. Bernstrand C, Sandstedt B, Åhström L, et al. Longterm followup of Langerhans cell histiocytosis: 39 years' experience at a single centre. Acta Pediatr 2005;94:1073-1084.
5. Stålemark H, Laurencikas E, Karis J, et al. Incidence of Langerhans cell histiocytosis in children: A population-based study. Pediatr Blood Cancer 2008;51:76-81.
6. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol 1996;14:2073-2082.
7. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004;42:438-444.
8. The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75:17-24.
9. Grois NG, Favara BE, Mostbeck GH, et al. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:287-305.
10. Nanduri VR, Bareille P, Pritchard J, et al. Growth and endocrine disorders in multisystem Langerhans' cell histiocytosis. Clin Endocrinol (Oxf) 2000;53:509-515.
11. Nanduri VR, Lillywhite L, Chapman C, et al. Cognitive outcome of long-term survivors of multisystem Langerhans cell histiocytosis: A single-institution, cross-sectional study. J Clin Oncol 2003;21:2961-2967.
12. Mittheisz E, Seidl R, Prayer D, et al. Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2007;48:50-56.
13. Prosch H, Grois N, Wnorowski M, et al. Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. Am J Neuroradiol 2007;28:1022-1028.
14. Prayer D, Grois N, Prosch H, et al. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. Am J Neuroradiol 2004;25:880-891.
15. Martin-Duverneuil N, Idbaih A, Hoang-Xuan K, et al. MRI features of neurodegenerative Langerhans cell histiocytosis. Eur Radiol 2006;16:2074-2082.
16. Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-2018.
17. Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 1996;7:267-272.
18. Blennow M, Sävman K, Ilves P, et al. Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr 2001;90:1171-1175.
19. Aurell A, Rosengren LE, Karlsson B, et al. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991;22:1254-1258.
20. Österlundh G, Kjellmer I, Lannering B, et al. Neurochemical markers of brain damage in cerebrospinal fluid during induction treatment of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2008;50:793-798.
21. Rosengren LE, Ahlsen G, Belfrage M, et al. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of children. J Neurosci Methods 1992;44:113-119.
22. Blennow K, Wallin A, Ågren H, et al. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231-245.
23. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
24. Sjögren M, Vanderstichele H, Ågren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values. Clin Chem 2001;47:1776-1781.
25. Van Gool SW, Van Kerschaver E, Brock P, et al. Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia 2000;14:2076-2084.
26. van Gool SW, De Meyer G, van de Voorde A, et al. Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology 2004;25:471-480.
27. Calming U, Henter JI. Elevated erythrocyte sedimentation rate and thrombocytosis as possible indicators of active disease in Langerhans' cell histiocytosis. Acta Paediatr 1998;87:1085-1087.
28. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzymelinked immunosorbent assay. J Neurochem 1993;61:1828-1834.
29. Teunissen CE, Dijkstra C, Palman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32-41.
30. Rosengren LE, Karlsson JE, Sjogren M, et al. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999;52:1090-1093.
31. Mandelkow E, Mandelkow EM. Microtubules and microtubule-associated proteins. Curr Opin Cell Biol 1995;7:72-81.
32. Trysberg E, Hoglund K, Svenungsson E, et al. Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Res Ther 2004;6:R129-R136.
33. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-212.
34. Janssens E, Aerssens P, Alliet P, et al. Post-dural puncture headaches in children. A literature review. Eur J Pediatr 2003;162:117-121.
35. Holst D, Möllmann M, Ebel C, et al. In vitro investigation of cerebrospinal fluid leakage after dural puncture with various spinal needles. Anesth Analg 1998;87:1331-1335.
36. Kebir H, Kreymborg K, Ifergan I, et al. Human T(H)17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Med 2007;13:1173-1175.
37. Grois N, Prayer D, Prosch H, et al. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 2005;128:829-838.
38. Allen CE, McClain KL. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med 2009;15:483-484, author reply 484-485.
39. Fadeel B, Henter JI. Langerhans cell histiocytosis: Neoplasia or unbridled inflammation? Trends Immunol 2003;24:409-410.
40. Bernstrand C, Carstensen H, Jakobsen B, et al. Immunogenetic heterogeneity in single-system and multisystem Langerhans cell histiocytosis. Pediatr Res 2003;54:30-36.